Free Courses In Business For October

Free Courses In Business For October | Poets and Quants

Get link
Facebook
X
Pinterest
Email
Other Apps

By Editorial Team - October 02, 2014

(Poetsandquants.com) -

Here are the MOOCs starting in early October. Click on the links below to learn more and enroll.

Successful Negotiation / October 6 / University of Michigan

Managing Fashion and Luxury Companies / October 3 / Università Bocconi

Giving 2.0 / October 6 / Stanford University

Beyond Silicon Valley: Growing Entrepreneurship in Transitioning Economies/ October 3 / Case Western Reserve University

Better Leader, Richer Life / October 5 / Wharton

Introduction to Finance / October 6 / University of Michigan

Copyright Clarity / October 6 / University of Rhode Island

Foundations of Business Strategy / October 6 / University of Virginia

Understanding Media By Understanding Google / October 6 / Northwestern University

What’s Your Big Idea? / October 6 / University of North Carolina

Game Theory / October 5 / Stanford University and the University of British Columbia

Model Thinking / October 6 / University of Michigan

Behavioural Economics in Action / October 6 / University of Toronto

Globalization’s Winners and Losers: Challenges for Developed and Developing Countries / October 7 / Georgetown University

Introduction to Decision Quality / October 9 / Strategic Decisions Group

The Power of Macroeconomics: Economic Principles in the Real World / October 6 / University of California-Irvine

The Power of Microeconomics: Economic Principles in the Real World / October 6 / University of California-Irvine

Additional Courses for Early October

Free business courses

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

AI Demand Drives Ongoing SSD & Memory Shortages: Prices Surging Further into 2026 and Beyond

By Editorial Team - January 19, 2026

As we enter 2026, the memory and storage crunch predicted in late 2025 has materialized with even greater intensity. AI data centers continue to dominate global production of DRAM and NAND flash, pushing prices sharply higher and extending lead times across consumer, PC, and enterprise segments. Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM sta...

Largest Pharma Companies in the World (2025–2026 Revenue Rankings)

By Editorial Team - February 07, 2026

Table of Contents: Largest Pharma Companies by Revenue (Global Ranking) Top 10 Pharmaceutical Companies by Market Cap in 2025 Top 10 Most Anticipated Drug Launches of 2025 Top 10 Drugs Losing US Exclusivity in 2025 The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders. In 2025, the biggest pharmaceutical companies by revenue continued to dominate through scale, research spending, and global distribution—despite growing pressure from patent expirations, biosimilars, and pricing reforms. Medical stocks are releasing earnings reports in droves. Eli Lilly and Co (LLY.US) targets $80 billion in 2026 revenue with standout performance; Novo-Nordisk A/S (NVO.US) beats Q4 expectations but lowers 2026 guidance due to pricing pressures. The largest pharma companies are defined not only by revenue, but by global scale, research investment, and thera...

Top 10 Food Companies by Revenue — 2026 Update

By Editorial Team - January 12, 2026

The ten largest food and beverage companies in the world remain Nestle, Ahold Delhaize, PepsiCo., Archer Daniels Midland, Sysco, JBS, Performance Food Group, Anheuser-Busch InBev, Unilever, and Tyson Foods. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This January 2026 update revises our original 2025 rankings using the latest available full-year 2024 results, 2025 trailing-twelve-month (TTM) data, and confirmed late-2025 corporate developments , including major mergers, recalls, and strategic restructurings. Top 10 Food Companies by Revenue This ranking reflects the largest companies primarily by annual revenue, emphasizing food production, processing, distri...

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies (2025 Year-End Version)

By Editorial Team - November 28, 2025

The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Updated Status as of November 2025 The core thesis from the original article remains valid: Bitcoin continues to behave like a high-beta tech asset with a strong positive correlation to the Nasdaq 100. However, the relationship has evolved with some important nuances in 2025. 30-day rolling correlation (BTC vs. Nasdaq 100) : ~0.80 → Highest level since 2022 and the second-highest in the past decade (sources: Kobeissi Letter, Wintermute, CoinDesk) 5-year average correlation : ~0.54 → Confirms the recent spike is part of a longer-term uptrend that began in 2020 Year-to-date performance (Jan 1 – Nov 20, 2025) : → Nasdaq 100: +20% → Bitcoin: +3–4% → BTC has significantly underperformed tech stocks despite the tight correlation Key new phenomenon in 2025 : Strong negativ...

Top AI and Robotic ETFs to Watch in 2026

By Editorial Team - December 08, 2025

As 2025 draws to a close, the fusion of artificial intelligence (AI) and robotics continues to redefine industries from manufacturing to healthcare. What began as a speculative tech boom has matured into tangible productivity gains, with global robotics market projections soaring from $94 billion in 2024 to potentially $373 billion by 2034. AI's role in enabling smarter automation—think humanoid robots in warehouses or surgical systems in operating rooms—positions these technologies as the backbone of the next industrial revolution. For investors eyeing 2026, exchange-traded funds (ETFs) offer a diversified gateway to this high-growth sector without the pitfalls of stock-picking volatility. Yet, the landscape isn't without challenges. Recent market jitters around AI hype have led to underperformance in some funds, but experts like Fidelity's Adam Benjamin highlight AI's "far-reaching" disruption potential, with capex from tech giants like Amazon and Microsoft ...

Top 10 ETFs to Buy in February 2026: Top Picks for Growth, Income, and Stability

By Editorial Team - February 02, 2026

As February 2026 begins, investors face a market defined by high valuations, persistent inflation risk, geopolitical uncertainty, and increasingly narrow equity leadership . The easy-money era is gone, but long-term opportunities remain — if ETFs are chosen for structure, not speculation . This list highlights the best ETFs to buy in February 2026, grouped by portfolio role, not hype. The goal is resilience, diversification, and intelligent exposure to themes that matter this year. How These ETFs Were Selected Each ETF was evaluated based on: Long-term performance and liquidity Expense ratio and fund structure Relevance to current macro conditions Usefulness within a diversified portfolio This is not a short-term trading list. These ETFs are best suited for investors with a multi-year horizon . Core Market ETFs (Foundation Holdings) These ETFs form the backbone of most long-term portfolios. 1. Vanguard S&P 500 ETF (VOO) Best for: Core U.S. equity exposure VOO remains one of the m...

Best Gold and Silver ETFs for February 2026: Investor Guide

By Editorial Team - February 03, 2026

February 2026 finds precious metals at an inflection point. After strong multi‑year rallies followed by sharp corrections — particularly in silver — investors are reassessing which gold and silver ETFs still make sense now , and which exposures carry unnecessary risk. This February 2026 update focuses on liquidity, cost, structure, and behavior during volatility , rather than past headline returns. The goal is not to predict metal prices, but to help investors choose the right vehicles for current conditions. Here are the standout gold and silver ETFs heading into February 2026, combining physically backed funds and miner-focused options (which posted triple-digit returns in 2025). Selections highlight 1 Year performance, AUM for dependability, and anticipated growth in precious metals amid inflation and geopolitical tensions. Data sourced from TradingView , Yahoo Finance, Investopedia, Investors.com, totalrealreturns.com, and recent analyses. Top Gold ETFs ...

Top Silver ETFs to Watch in 2026: What Investors Need to Know (February 2026)

By Editorial Team - February 02, 2026

After its outsized gains in 2024–2025, silver experienced a sharp pullback entering February 2026 — a move that surprised many late-cycle buyers but was consistent with historical silver bull markets. This correction was driven by several overlapping factors: Profit-taking after extreme gains , particularly in leveraged and mining-linked products A stronger U.S. dollar and shifting rate expectations , which temporarily pressured precious metals Speculative positioning unwinds , as futures and options markets became crowded Equity market rotation , drawing capital back toward risk assets Importantly, the pullback did not coincide with a collapse in industrial demand or a sudden resolution of supply constraints. As a result, many analysts view the move as a volatility reset rather th...

NVIDIA vs AMD GPUs for AI: 2026 Comparison and Recommendations

By Editorial Team - January 24, 2026

In the rapidly evolving world of AI in 2026, choosing between NVIDIA and AMD GPUs boils down to ecosystem maturity, performance needs, and budget. NVIDIA GPUs generally lead in AI performance, particularly for short- to medium-term rentals, due to their larger market presence and competitive pricing. However, AMD has been enhancing its offerings and can outperform NVIDIA in certain workloads, so the best choice depends on the specific use case. NVIDIA's dominance stems from its CUDA platform, which powers over 90% of AI frameworks, while AMD is gaining ground with ROCm's open-source approach and cost-effective hardware. AMD's Instinct MI300X and upcoming MI350 series offer competitive inference speeds, sometimes at 40% better efficiency than NVIDIA's Blackwell. This article compares their architectures, benchmarks for AI tasks like training and inference, and provides tailored recommendations with Amazon links for accessible models. Key Differences Between NVIDIA and ...

Top 10 Drugs by Worldwide Sales in 2025

By Editorial Team - October 04, 2025

The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025. Summary 1. Keytruda (Merck): 31B 2. Ozempic (Novo Nordisk): 21 B 3. Mounjaro (ELi Lilly): 19 B 4. Dupixent (Sanofi and Regeneron): 17 B 5. Wegovy (Novo Nordisk): 14 B 6. Biktarvy (Gilead Sciences): 13.4 B 7. Skyrizi (Abbvie): 13 B 8. Eliquis (Bristol-Myers Squibb): 13 B 9. Darzalex (Johnson & Johnson): 13 B 10. Humira (Abbvie): 12.5 B Highlights and Market Trends Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year...

Search This Blog

Consumer Advisor